Immunai

Decoding the Immune System to Improve Health

[Immunai @Immunaitech]

World Cancer Day is about progress. And progress starts with better insight.
We’re proud to work with @bmsnews to apply AI-powered immune analysis that helps researchers better understand patient responses and support smarter therapy development.

https://t.co/buQkuOxLPA

[Immunai @Immunaitech]

Understanding patient immune response is critical to clinical development (and difficult to do well).

We’re collaborating with @BMSnews to support immune-driven clinical development, using AMICA-OS™, our immune system AI operating system.

Read more:
https://t.co/bltHepTtlR

[Immunai @Immunaitech]

@MountSinai , @WeillCornell Medicine, and Harvard’s @MassGeneral are the first academic partners in Immunai’s Grand Collaboration Initiative. We’re teaming up to apply single-cell immune insights at scale and accelerate discovery.

The announcement: https://t.co/sHhqw4pdyh

[Immunai @Immunaitech]

Big news: @Immunai has won the @FierceBiotech Life Sciences Award for AI Innovation. Fierce showcased our AMICA™ platform and its success in forecasting patient response - a major step toward more precise development. https://t.co/zpCSBL2BYW

[Immunai @Immunaitech]

New in Blood Advances: our Immunai team, with Mount Sinai & Janssen R&D, identified immune features predicting long-term response to CAR T therapy in multiple myeloma.
🔗 https://t.co/CvQ37xEoUR
#Immunai #CART #MultipleMyeloma #Immunotherapy #PrecisionMedicine

[Immunai @Immunaitech]

Immunai has been named a finalist in the @FierceHealth : Life Sciences Edition 2025 (AI Innovation category)! Our AMICA™, CT-OS™, and PE-OS™ platforms are driving a new wave of immune intelligence, where AI helps predict, not just treat, disease. https://t.co/nsbnEIJvD4

[Immunai @Immunaitech]

Proud to expand our work with @AstraZeneca into inflammatory bowel disease. IBD affects 10M+ people worldwide, with many still cycling through treatments. With Immunai’s IDE™ and AMICA™, we’re uncovering and exploring new immune targets. @FierceBiotech: https://t.co/ISS72FQdcL

[Immunai @Immunaitech]

Research in immunity can’t wait for funding. We launched the Grand Collaboration Initiative to give researchers free access to immune mapping tools: accelerating discoveries in cancer, autoimmunity, and beyond. More in @PharmaVoice https://t.co/m4O4vXSSv1

[Immunai @Immunaitech]

Research in immunity can’t wait for funding. Immunai’s Grand Collaboration Initiative is giving researchers free access to our immune mapping tools to speed discoveries in cancer, autoimmunity, and more. https://t.co/kQ4pEgpAQg

[Immunai @Immunaitech]

Immunai’s Grand Collaboration is now open!
Single-cell immune sequencing for academic researchers to advance immune system understanding.
✔️ High-resolution, multi-omic data
🧬 Enrichment of the AMICA atlas
🗓️ Applications due by Oct 1, 2025
#scRNAseq #Immunai #AcademicResearch

[Immunai @Immunaitech]

Excited to share our work at #BiomedIsrael! Elisha Nathan presents how Immunai de-risks immunotherapy development using AI + single-cell multi-omics. Powered by AMICA, the world’s largest clinical immune db. #Immunai #DrugDevelopment #Oncology #Autoimmune

[Immunai @Immunaitech]

Our CEO @NoamSolomon1 just joined a very impressive club: @INVIVOnow’s 2025 Rising Leaders💥 This list features 30 people shaking up biotech, medtech, and global health.

Proud moment for the @Immunaitech team. https://t.co/sFC3v7PwUT

[Immunai @Immunaitech]

At #DDW2025, Immunai & @AstraZeneca share new IBD research using single-cell data + functional genomics. Deleting one target reduced TNFα/IFNγ in macrophages - showing real therapeutic potential.
📷 Read more: https://t.co/UOiCPIUfRW
 #IBD #Immunology #DrugDiscovery #AIinBiotech

[Immunai @Immunaitech]

We’re teaming up with @parkerici to build one of the largest real-world single-cell datasets. Integrated into AMICA™, this will power immune insights across cancers, accelerating discovery + reducing trial risk
https://t.co/EQiUt0b4sN

[Immunai @Immunaitech]

🧬 Heading to #AACR25? Meet Immunai CEO Noam Solomon, CTO Adeeb Rahman, & VP BD Evan Zisholtz
📌 See our April 30 poster on predicting aPD1 response using a human ex vivo tumor model + multiomic data.

#Immunotherapy #CancerResearch #Multiomics

[Immunai @Immunaitech]

After leading R&D at Pfizer, Dr. Mikael Dolsten is entering a new chapter. He’s joining Immunai’s board to help advance AI-powered drug development.

Read about his move and outlook on the future of biopharma via @PharmaVoice: https://t.co/HH56p2BVbG

[Immunai @Immunaitech]

Dr. Mikael Dolsten, a leader behind 35+ approved therapies, is bringing his expertise to Immunai’s Board. His experience in R&D and immunology will help us deepen AI’s role in drug discovery, bringing new treatments to patients faster. https://t.co/8LtLUccNCq

[Immunai @Immunaitech]

🧬 Inside Immunai kicks off 2025 with Eva Macuchova, our Scientific Team Lead! At Immunai, she’s helped standardize data & fuel AI-powered discoveries in cancer & inflammatory research.

Crime novel lover, foodie, & data expert—join her team! https://t.co/jPsvUzXH1w

[Immunai @Immunaitech]

Immunai has been named Startup of the Week via @theinnovator⭐️
Read how Immunai is bridging the gap between computer science and life sciences to combat Eroom’s Law—the rising costs of drug development.https://t.co/hozNm0FLJh

[Immunai @Immunaitech]

Our CEO @NoamSolomon1 is headed to Davos to represent Immunai as part of the @WEF Unicorn Program with other high-growth companies shaping the future of their industries. Are you attending? https://t.co/jRNMbIhxwY